Fonatinib for leukemia treatment is effective...Need to expand salary and further research
Feb 06, 2025
"Recently, treatment with Ponatinib (phonatinib) in the treatment of Philadelphia chromosome-positive acute lymphocytic leukemia (PH+ALL) is suggesting a new direction. However, in the future, pay expansion and further research are needed to ensure that fornatinib can be used more widely in Ph+ ALL patients."
Lee Jong-hyuk, a professor of hematologic oncology at the Catholic University of Korea's Incheon St. Mary's Hospital, recently attended a forum on the theme of 'the latest knowledge on foratinib in patients with Ph+ ALL' as a panel. This discussion was attended by domestic hematologists to share various opinions, including the latest treatment strategies and clinical experiences centered on foratinib in Ph+ ALL treatment.
Professor Lee Jong-hyuk, Professor Kim Dong-yoon of the Catholic University of Korea's Yeouido St. Mary's Hospital, Professor Kim Byung-soo of the Catholic University of Korea's Eunpyeong St. Mary's Hospital, Professor Yoon Seok-yoon of Soonchunhyang University's Seoul Hospital, and Professor Lee Joon-yeop of the Catholic University's Eunpyeong St. Mary's Hospital attended the panel to discuss.
Ph+ ALL is a disease with a poor prognosis among acute lymphocytic leukemia (ALL), and the development of treatment strategies is urgent. It is found in 30% to 40% of all ALL. Recently, a new approach to Ph+ ALL treatment has been actively underway in Korea.
Professor Lee Jong-hyuk said, "In the current treatment of Ph+ ALL, fonatinib and Hyper-CVAD combination therapy have become effective options available as first-line treatments. Starting with 45mg in induction therapy, the dose is adjusted according to the patient's response, which can be reduced to 15mg if the full molecular response (CMR) is reached. Through this, we can maximize the therapeutic effect while minimizing side effects.'
According to a combination study of phonatinib and Hyper-CVAD conducted on new Ph+ ALL patients at the MDACC (MD Anderson Cancer Center), it showed excellent response rates with 100% complete remission rate, 100% complete cell genetic response rate, 95% major molecular response rate, and 87% complete molecular response rate. In addition, the 6-year survival rate (EFS) was 65% and the 6-year overall survival rate (OS) was 75%, showing a significant improvement compared to the survival rate of existing treatments.
Professor Lee Jong-hyuk evaluated this as "significantly better results than the previous case of using imatinib or dasatinib" and "This suggests that foratinib shows superior effects compared to the first and second generations of TKI."
Regarding the safety of fonatinib, Professor Lee said "Although there is concern about cardiovascular adverse reactions, it can be managed through a strategy of gradual reduction after initial high-dose use and continuous monitoring."Even in domestic cases, it was rare that treatment had to be stopped due to side effects, and most of them were able to continue treatment stably through dose control", he explained.
Finally, Professor Lee Jong-hyuk believes that there is a great need for maintenance therapy after hematopoietic stem cell transplantation using phonatinib. This will reduce the risk of recurrence and further increase the survival rate of patients"In the future, we need to expand pay and further research to ensure that foratinib can be used more widely in Ph+ ALL patients."
Meanwhile, Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) and is one of the target anticancer drugs used to treat leukemia. It is specifically used to treat blood cancers such as Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL). Ponatinib has an excellent response rate and survival rate even in patients who are resistant to conventional first-generation (TKI) or second-generation (TKI), dasatinib, making it a new standard in the treatment of Ph+ ALL.
Lee Jong-hyuk, a professor of hematologic oncology at the Catholic University of Korea's Incheon St. Mary's Hospital, recently attended a forum on the theme of 'the latest knowledge on foratinib in patients with Ph+ ALL' as a panel. This discussion was attended by domestic hematologists to share various opinions, including the latest treatment strategies and clinical experiences centered on foratinib in Ph+ ALL treatment.
Professor Lee Jong-hyuk, Professor Kim Dong-yoon of the Catholic University of Korea's Yeouido St. Mary's Hospital, Professor Kim Byung-soo of the Catholic University of Korea's Eunpyeong St. Mary's Hospital, Professor Yoon Seok-yoon of Soonchunhyang University's Seoul Hospital, and Professor Lee Joon-yeop of the Catholic University's Eunpyeong St. Mary's Hospital attended the panel to discuss.
Ph+ ALL is a disease with a poor prognosis among acute lymphocytic leukemia (ALL), and the development of treatment strategies is urgent. It is found in 30% to 40% of all ALL. Recently, a new approach to Ph+ ALL treatment has been actively underway in Korea.
Professor Lee Jong-hyuk said, "In the current treatment of Ph+ ALL, fonatinib and Hyper-CVAD combination therapy have become effective options available as first-line treatments. Starting with 45mg in induction therapy, the dose is adjusted according to the patient's response, which can be reduced to 15mg if the full molecular response (CMR) is reached. Through this, we can maximize the therapeutic effect while minimizing side effects.'
According to a combination study of phonatinib and Hyper-CVAD conducted on new Ph+ ALL patients at the MDACC (MD Anderson Cancer Center), it showed excellent response rates with 100% complete remission rate, 100% complete cell genetic response rate, 95% major molecular response rate, and 87% complete molecular response rate. In addition, the 6-year survival rate (EFS) was 65% and the 6-year overall survival rate (OS) was 75%, showing a significant improvement compared to the survival rate of existing treatments.
Professor Lee Jong-hyuk evaluated this as "significantly better results than the previous case of using imatinib or dasatinib" and "This suggests that foratinib shows superior effects compared to the first and second generations of TKI."
Regarding the safety of fonatinib, Professor Lee said "Although there is concern about cardiovascular adverse reactions, it can be managed through a strategy of gradual reduction after initial high-dose use and continuous monitoring."Even in domestic cases, it was rare that treatment had to be stopped due to side effects, and most of them were able to continue treatment stably through dose control", he explained.
Finally, Professor Lee Jong-hyuk believes that there is a great need for maintenance therapy after hematopoietic stem cell transplantation using phonatinib. This will reduce the risk of recurrence and further increase the survival rate of patients"In the future, we need to expand pay and further research to ensure that foratinib can be used more widely in Ph+ ALL patients."
Meanwhile, Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) and is one of the target anticancer drugs used to treat leukemia. It is specifically used to treat blood cancers such as Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL). Ponatinib has an excellent response rate and survival rate even in patients who are resistant to conventional first-generation (TKI) or second-generation (TKI), dasatinib, making it a new standard in the treatment of Ph+ ALL.
|
This article was translated by Naver AI translator.
